Multi-drug resistant tuberculosis (MDR-TB) poses grave challenge because of prolonged, limited and expensive treatment options with 10 to 30 per cent of cases resulting in failure of treatment and death[@ref1]. Timely diagnosis and prompt treatment of infectious cases is crucial in curtailing the spread of infection in the community. Conventional drug susceptibility (DST) has been the gold standard but takes upto 4-6 wk after the growth of bacteria. Liquid culture methods, are sensitive and faster but involve prohibitive expenditure[@ref2]. Commercial line probe assays (LPAs) based on reverse hybridization of amplicons to immobilized membrane based probes covering wild type and mutation sequences have been developed for rapid detection of MDR-TB[@ref3]. Results of GenoType MTBDR*plus* for rifampicin (RIF) and isoniazid (INH) resistance are comparable to conventional DST[@ref4]. Rifampicin resistance is caused by a mis-sense mutation in the beta-subunit of DNA dependent RNA polymerase in 81-bp hotspot region of *rpo*B gene. Resistance to INH is most frequently associated with mutations in *kat G* gene and *inh*A gene[@ref5].

The Programmatic Management of Drug Resistant Tuberculosis (PMDT) guidelines in India, identify MDR-TB in suspects using GenoType MTBDR*plus* (WHO approved) only where it is available[@ref6]. The National Institute of Tuberculosis and Respiratory Diseases, New Delhi, India is a referral TB hospital and National Reference Laboratory (NRL) for North-Eastern States of India. There are barely any data on MDR-TB from North-East (NE) India. Therefore, this study was aimed at detection of MDR-TB among MDR-TB suspects and common mutations in *rpo*B, *kat*G and *inh*A genes using GenoType MTBDR*plus* in the N-E region.

Material & Methods {#sec1-1}
==================

A total of 553 sputum samples from MDR-TB suspect patients from seven North-Eastern States namely Arunachal Pradesh; 121, Assam; 95, Manipur; 75, Meghalaya; 97, Mizoram 89, Nagaland; 46 and Tripura 30 collected during January 2012 to August 2012 were received in the Microbiology Department of the Institute at New Delhi, India. The samples were collected from the patients in each peripheral designated microscopy centres (DMC) in the above States and transported in cold-chain as per PMDT guidelines to this laboratory[@ref6]. The collection and transport was supervised by the district TB officers (DTOs) in the States. The MDR-suspect patients enrolled under PMDT in these States included TB patients who were either on category I anti-tubercular treatment with fifth month follow up smear positive for acid-fast bacilli (AFB), or category II treatment with four month follow up AFB smear positive or contacts of MDR-TB (Criterion A)[@ref6]. The study protocol was approved by institute\'s ethical committee.

*Sample processing*: All specimens were screened for presence of AFB by Ziehl-Neelsen (ZN) staining[@ref7]. The samples were processed by N-acetyl-L-cysteine-Sodium hydroxide (NALC-NaOH) method of digestion and decontamination[@ref8]. All smear positive (\> 1+ AFB) sputum samples received within 72 h of sample collection in cold chain were subjected to only LPA after NALC-NaOH processing whereas the remaining samples including smear negative and scanty AFB positive were subjected to culture as per PMDT guidelines[@ref3][@ref6].

*Culture*: For culture, processed samples were inoculated in MGIT 960 tubes. Tubes flashed positive were identified for *Mycobacterium tuberculosis* by smear microscopy (serpentine cording) and rapid immuno-chromatographic test (MPT64 TB Ag detection). Cultures positive for *M. tuberculosis* were subjected to LPA.

*Line probe assay*: The GenoType MTBDR*plus* assay (Hain Life Sciences, Nehran, Germany) was carried out as per manufacturer\'s instructions[@ref3]. DNA extraction, master-mix preparation, DNA amplification and hybridization were done after thorough cleaning in separate dedicated rooms[@ref3]. For DNA extraction from NaLC-NaOH processed sample and culture, 500 μl and 1 ml aliquots, respectively were taken. Final DNA obtained was subjected to amplification and the rest was stored at - 20°C[@ref3].

Master-mix was prepared using reagents provided in the kit in 45 μl volume to which 5 μl DNA was added[@ref3]. The PCR products were detected by hybridization using LPA methodology[@ref3]. The result of DNA strips was interpreted with the help of reporting card as resistant or sensitive for RIF and INH. The presence or absence of all wild type and mutant bands was recorded systematically[@ref3].

The reports were communicated electronically to the TB co-ordinators of the respective States. The LPA on any invalid results were repeated using stored processed sample deposits. In each run, *M. tuberculosis* H37Rv (ATCC 27294) and sterile molecular grade water were included as positive and negative controls, respectively.

Results {#sec1-2}
=======

Of the 553 patients, 390 were males and 163 were females with a male: female ratio of 2.4: 1. In Tripura, 27 of 30 (90%) of suspects were males. Most patients (424 of 553, 76.7%) belonged to the age group of 15-45 yr which included 224 (40.5%) in the age group 15-29 and 200 (36.2%) in age group 30-45; 113 patients were more than 45 yr whereas 16 were less than 15 years.

The smear microscopy results are given in [Table I](#T1){ref-type="table"}. The smear positive and negative patients were 372 (67.3%) and 181 (32.7%), respectively. A total of 339 GenoType MTBDR*plus* were conducted which included 43 culture isolates obtained from smear negatives/scanty positive cultures. The State-wise data of LPA is detailed in [Table II](#T2){ref-type="table"}. Valid LPA results were obtained for 328 of 339 (97.8%) strains. Of the 328, 181 (55.2%) tests were found to be resistant to both RIF and INH, 28 (8.5%) were resistant to RIF only, 29 (8.8%) were resistant to INH only and the remaining 90 (27.4%) were sensitive to both RIF and INH. The total RIF resistant cases diagnosed were 209 (63.7%). The LPA result to these states from cultures and samples could be dispatched in an average of 23.4 days and 5.2 days respectively from reviewing of the sample. The TAT of DST using LPA was reduced significantly by 93.5 per cent as compared to solid culture DST (9-12 wk).

###### 

State-wise distribution of AFB smear positive and negative samples; AFB reporting as per RNTCP guidelines
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###### 

Rifampicin and isoniazid susceptibility result using GenoType MTBDR*plus*
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The mutations responsible for RIF and INH resistance are displayed in [Table III](#T3){ref-type="table"}. Among 209 RIF resistant isolates, missing WT (wild type) along with known mutations could be detected in 165 (78.9%). Commonest known RIF mutation was in codon S531L (136/209; 65.1%) followed by D516V mutation (15/209; 7.2%), H526Y mutation (12/209; 5.7%) and H526D mutation (4/209; 1.9%). In 44 (21.1%) RIF resistants, one or more wild type probes were missing with no bands in mutant probes. These 44 included missing WT8 (11; 25 %), missing WT3/ WT4 (9; 20.5%), missing WT2 (7; 15.9%), missing WT7 (5; 11.4%), missing WT1/ WT2 (2; 4.5%), missing WT3 (2; 4.5%), missing WT2/WT3 (1; 2.3%), missing WT2/WT3/W4 (1; 2.3%) missing WT2/WT7 (1; 2.3%), missing WT3/WT4/W8 (1; 2.3%), missing WT4 (1; 2.3%), missing WT4/ WT5 (1; 2.3%), missing WT4/ WT8 (1; 2.3%) and missing WT5/ WT6 (1; 2.3%). Mixed pattern to RIF with all wild type probes present along with presence of one or more mutant bands was found in 7.7 per cent (16/209), commonest being S531L (10; 66.7%).

###### 

Pattern of gene mutations detected by GenoType MTBDR*plus* assay in drug resistant *M. tuberculosis*
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Among 210 INH resistant isolates as detected by MTBDR*plus*, *kat*G mutations occurred in 192 (91.4%). Mutations in codon S315T1 were detected in 179 (85.2%) of INH resistant or 179 of 192 (93.2%) of *kat*G mutants. Missing wild types with unknown mutant probe among *kat*G were found in 11(5.7%). Mutations in *Inh*A were found in 23 (10.96%) INH resistants, which included 20 (86.95%) C15T and 1 (4.3%) T8C. Both *inh*A and *kat*G mutations were seen in 5/210 (2.4%) INH resistants. Mixed wild-type and mutant pattern to INH was found in 19 per cent (4/209).

Discussion {#sec1-3}
==========

Till August 2012, all samples from the region were referred to our institute due to lack of culture and DST or LPA facility. The implementation of TB control in these States is challenging due to poor accessibility, difficult geographical terrains, weak infrastructure and politico-social issues. Males were predominant with 70.5 per cent and majority patients belonged to the young age group of 15-45 yr as is also seen in other studies[@ref9]. High MDR-TB burden in young adult males have many socio-economic implications. High percentage of MDR-TB of 32.7 per cent among MDR suspects was found in the study. In India, MDR-TB rates have been found to be 17.4 to 53 per cent among previously treated cases who are more likely to develop multi-drug resistance[@ref10][@ref11][@ref12].

The average turn-around time (TAT) for LPA was 5.2 days which was slightly higher than that recommended by RNTCP. Theoretically, LPA is completed in less than 72 h but direct microscopy for screening for AFB, NALC-NaOH processing and detailed report typing adds on more days. After amplification, maximum of 20 DNA could be hybridized in one working day on twin-incubator, which added to delay. Other reasons included repeat LPA due to inconclusive results, erratic internet connectivity and holidays.

However, such patients were started on category IV treatment within 1 wk of report communication, thereby curtailing the spread of the diseases.

The GenoType MTBDR*plus* detects the mutations for RIF and INH, which highly correlate with the sequencing[@ref13]. In the present study, the test identified RIF resistance by one of four *rpo*B mutant probes in 78.9 per cent strains, much lesser than in South African study (88.6%)[@ref14]. Mutation in codon S531L was detected in 65.1 per cent of RIF resistants, whereas other Indian studies found it in 59.8 and 84.6 per cent cases[@ref15][@ref16]. Internationally, S531L mutation has been detected in rates varying from 47 to 70.5 per cent[@ref3][@ref14][@ref17][@ref18]. In some studies S531L mutation occurred more frequently in MDR isolates in comparison to RIF mono-resistants[@ref14][@ref17]. However, we did not find any such difference. The missing wild type probe without any mutant bands was found in 21.1 per cent of RIF resistants as also reported in other studies, New Delhi; 11.1 per cent, Vietnam; 33.3 per cent, France; 29 per cent, Uganda; 42.1 per cent[@ref16][@ref18][@ref3][@ref17]. In GenoType MTBDR*plus* the entire wild type region is covered by wild type probes whereas only common mutant probes are covered. As per the kit insert provided, absence of any wild type band along with presence or absence of mutant band, accounts for resistance. Such isolates with uncommon mutations could have been identified by sequencing. One limitation of the study was the inability to perform sequencing due to lack of such set up in this facility.

*kat*G mutations account for commonest mechanism of resistance for INH. Specific mutation in codon S315T1 of *kat*G was found in 86.2 per cent of INH resistant isolates, similar to other studies[@ref17][@ref19][@ref21]. Variations have been reported from France; 62.5 per cent, Uganda; 61.5 per cent and South Africa; 37.6%[@ref3][@ref17][@ref14]. High prevalence of *kat*G mutations accounts for more INH resistance in high burden countries and high-level INH resistance[@ref19].

Mutation in *inh*A gene accounts for 15-20 per cent of all INH resistant cases and low-level resistance. It was found to be 11.0 per cent, similar to studies elsewhere 5.4 to 21.1 per cent[@ref3][@ref17][@ref18][@ref20]. However, Barnard *et al*[@ref14] reported high prevalence of *inh*A mutations (41.7%). They also found significant difference in prevalence of mutations in MDR strains as compared to mono-INH resistants[@ref14]. We did not find any such difference.

Heteroresistance defined as presence of all wild type probes along with presence of one or more mutant bands was found in 7.7 per cent of RIF resistant and in 1.9 per cent of INH resistant isolates unlike a study from Mumbai[@ref21]. A disadvantage of any genotypic test is a possibility of silent mutation, *i.e*. mutations which do not lead to change in amino acid hence not leading to phenotypic drug resistance. Resistance originating from mutation of other genes as well as other resistant mechanisms will not be detected by this test. Such mutations could be detected by sequencing.

In conclusion, our study shows the resistance to RIF and INH among *M. tuberculosis* isolates obtained from MDR-TB suspects of North-Eastern region of India using the GenoType MTBDR*plus* assay. In addition, information on the common mutations in the *rpo*B, *kat*G and *inh*A regions associated with resistance in also provided.
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